Journal of Neurology Research, ISSN 1923-2845 print, 1923-2853 online, Open Access
Article copyright, the authors; Journal compilation copyright, J Neurol Res and Elmer Press Inc
Journal website

Case Report

Volume 10, Number 1, February 2020, pages 20-24

Acute Reversible Cerebral Vasoconstriction Syndrome With Low-Dose Dihydroergotamine Possibly Potentiated by Valproic Acid and Erenumab: A Case Report


Figure 1.
Figure 1. Time course of vital signs and medications administered to the patient during the hospitalization. All medications were intravenous formulation except oral preventives, methadone/morphine, and verapamil. All doses are in mg except where noted. Red arrow indicates the time of PRES/RCVS onset. PRES: posterior reversible encephalopathy syndrome; RCVS: reversible cerebral vasoconstriction syndrome; NSAID: non-steroidal anti-inflammatory drug.
Figure 2.
Figure 2. MRI and MRA of the brain. (a) FLAIR image showed hyperintensity in the posterior parietal and occipital lobes. (b) DWI image showed small bilateral occipital pole diffusion restrictions. (c) GRE image showed right occipital curvilinear superficial siderosis. (d) and (e) Segmental narrowing of bilateral ACA, MCA, PCA, and BA. MRI: magnetic resonance imaging; MRA: magnetic resonance angiography; FLAIR: fluid-attenuated inversion recovery; DWI: diffusion-weighted imaging; GRE: gradient-recalled echo; ACA: anterior cerebral artery; MCA: middle cerebral artery; PCA: posterior cerebral artery; BA: basilar artery.